[go: up one dir, main page]

AR037778A1 - Suplementacion mediada por plasmido para el tratamiento de sujetos cronicamente enfermos - Google Patents

Suplementacion mediada por plasmido para el tratamiento de sujetos cronicamente enfermos

Info

Publication number
AR037778A1
AR037778A1 ARP020104785A ARP020104785A AR037778A1 AR 037778 A1 AR037778 A1 AR 037778A1 AR P020104785 A ARP020104785 A AR P020104785A AR P020104785 A ARP020104785 A AR P020104785A AR 037778 A1 AR037778 A1 AR 037778A1
Authority
AR
Argentina
Prior art keywords
seqid
nucleic acid
ghrh
expression construct
animal
Prior art date
Application number
ARP020104785A
Other languages
English (en)
Inventor
Robert H Carpenter
Douglas R Kern
Robert J Schwartz
Glen King
Kevin Hahn
Malcom K Brenner
Ruxandra Draghia-Akli
Original Assignee
Advisys Inc
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advisys Inc, Baylor College Medicine filed Critical Advisys Inc
Publication of AR037778A1 publication Critical patent/AR037778A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/25Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composiciones y métodos de suplementación mediada por plásmido. Las composiciones y métodos son útiles para retrasar el crecimiento de un tumor y retrasar la caquexia, deterioro, anemia y otros efectos que están comúnmente asociados en los animales portadores de cáncer. La realización se lleva a cabo liberando una cantidad efectiva de una construcción de expresión de ácido nucleico que codifica una GHRH o un equivalente biológico funcional de la misma dentro del tejido de un animal y permitiendo la expresión en el animal del gen codificado. Por ejemplo, cuyo tales secuencias de ácido nucleico son liberados dentro de células específicas del tejido animal específico, se lleva a cabo la expresión constitutiva. Además, se puede llevar a cabo la regulación externa del gen de GHRH o del equivalente biológico funcional utilizando promotores inducibles que son regulados por moléculas interruptoras moleculares, las cuales son incorporadas en el animal. El método preferido para liberar la secuencia de ácido nucleico codificante constitutiva o inducible de GHRH o del equivalente biológico funcional de la misma es directamente dentro de las células del animal mediante el proceso de electroporación in vivo. Además, un tratamiento para retardar el crecimiento del tumor y retrasar la caquexia o los efectos del deterioro que están comúnmente asociados con los tumores, se lleva a cabo mediante la liberación dentro del animal de GHRH recombinante o el equivalente biológico. Reivindicación 4: El método de la reivindicación 1, en donde la construcción de expresión de ácido nucleico comprende la SeqID N°: 11, SeqID N°: 12, SeqID N°: 13, SeqID N°: 14, SeqID N°:17, SeqID N°: 18, SeqID N°:19, SeqID N°: 20 ó SeqID N°: 21. Reivindicación 8: El método de la reivindicación 1, en donde la liberación dentro de las células del sujeto de la construcción de expresión de ácido nucleico inicia la expresión de la GHRH codificada o el equivalente biológico funcional de la misma. Reivindicación 12: El método de la reivindicación 8, en donde la GHRH codifica o el equivalente biológico funcional codificado de la misma es de la fórmula (SeqID N°: 6): X-1-X2-DAIFTNSYRKVL-X3-QLSARKLLQDI-X4-X5-RQQGERNQEQGA-OH en donde la fórmula tiene las siguientes características: X-1 es isómero -L o -D de un aminoácido tirosina ("Y"), o histidina ("H"); X2 es un isómero -L o -D del aminoácido alanina ("A"), valina ("V"), o isoleucina ("I"); X3 es un isómero -L o -D del mismo aminoácido alanina ("A") o glicina ("G"); X4 es un isómero -L o -D del aminoácido metionina ("M"), o leucina ("L"); X5 es un isómero -L o -D del aminoácido serina ("S") o asparragina ("N"); o una combinación de los mismos. Reivindicación 13: El método de la reivindicación 1, en donde la construcción de expresión de ácido nucleico codifica un polipéptido de una secuencia que comprende la SeqID N°: 1, SeqID N°: 2, SeqID N°: 3, o SeqID N°: 4. Reivindicación 15: El método de tratamiento de la anemia en un sujeto, que comprende: (a) liberar dentro de las células del sujeto una cantidad específica de una primera construcción de expresión de ácido nucleico, y una cantidad específica de una segunda construcción de expresión de ácido nucleico; en donde la primer construcción de expresión de ácido nucleico codifica a la hormona liberadora de la hormona de crecimiento ("GHRH") o un equivalente biológico funcional de la misma; y en donde la segunda construcción de expresión de ácido nucleico tiene una región codificante de una proteína reguladora; y (b) liberar una molécula interruptor molecular dentro del sujeto, en donde la molécula interruptor molecular gobierna la activación de al proteína reguladora.
ARP020104785A 2001-12-11 2002-12-10 Suplementacion mediada por plasmido para el tratamiento de sujetos cronicamente enfermos AR037778A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33961001P 2001-12-11 2001-12-11

Publications (1)

Publication Number Publication Date
AR037778A1 true AR037778A1 (es) 2004-12-01

Family

ID=23329825

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020104785A AR037778A1 (es) 2001-12-11 2002-12-10 Suplementacion mediada por plasmido para el tratamiento de sujetos cronicamente enfermos

Country Status (11)

Country Link
US (2) US7241744B2 (es)
EP (1) EP1465654B1 (es)
CN (1) CN1615151A (es)
AR (1) AR037778A1 (es)
AU (1) AU2002357143B2 (es)
BR (1) BR0214869A (es)
CA (1) CA2469310C (es)
MX (1) MXPA04005713A (es)
MY (1) MY142457A (es)
TW (1) TW200301778A (es)
WO (1) WO2003049700A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1578901A4 (en) * 2001-09-07 2006-03-29 Baylor College Medicine LINEAR DNA FRAGMENTS FOR GENE EXPRESSION
CN100417419C (zh) * 2001-10-26 2008-09-10 贝勒医学院 改变个体的瘦体重和骨特性的组合物和方法
AR037778A1 (es) * 2001-12-11 2004-12-01 Advisys Inc Suplementacion mediada por plasmido para el tratamiento de sujetos cronicamente enfermos
TW200307749A (en) * 2002-02-07 2003-12-16 Baylor College Medicine Modified pituitary gland development in offspring from expectant mother animals treated with growth hormone releasing hormone therapy
CN1662261A (zh) * 2002-05-28 2005-08-31 阿德维希斯公司 通过多聚-l-谷氨酸(“plg”)系统增加核酸构建体的体内递送
TWI290174B (en) * 2002-11-04 2007-11-21 Advisys Inc Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
TW200424214A (en) * 2003-04-21 2004-11-16 Advisys Inc Plasmid mediated GHRH supplementation for renal failures
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
CA2575926C (en) * 2003-08-04 2014-02-25 Advisys, Inc. Canine specific growth hormone releasing hormone
CN101027081A (zh) * 2004-07-23 2007-08-29 阿德维希斯公司 生长激素释放激素增强疫苗接种应答
US7846720B2 (en) * 2005-01-26 2010-12-07 Vgx Pharmaceuticals, Inc. Optimized high yield synthetic plasmids
DE602006013117D1 (de) 2005-04-25 2010-05-06 Merial Ltd Nipah-virus-impfstoffe
EP1951751B1 (en) 2005-11-14 2017-11-01 Merial, Inc. Gene therapy for renal failure
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
US8980249B2 (en) 2010-06-03 2015-03-17 University Of Miami Agonists of growth hormone releasing hormone as effectors for survival and proliferation of pancreatic islets
US9216213B2 (en) 2011-04-20 2015-12-22 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
US8993316B2 (en) 2011-11-16 2015-03-31 Brian P. Hanley Methods and compositions for gene therapy and GHRH therapy
US9079974B2 (en) * 2011-12-21 2015-07-14 The University Of Miami GH-RH analogs with potent agonistic effects
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
EP2935317B1 (en) 2012-12-21 2019-03-27 University of Miami Ghrh agonists for islet cell transplantation and function and the treatment of diabetes
EP2934565B1 (en) 2012-12-21 2019-03-13 University of Miami Ghrh agonists for the treatment of ischemic disorders

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4223020A (en) 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223019A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4226857A (en) * 1979-03-30 1980-10-07 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4224316A (en) 1979-03-30 1980-09-23 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223021A (en) 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228158A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228156A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4410512A (en) * 1981-12-28 1983-10-18 Beckman Instruments, Inc. Combinations having synergistic pituitary growth hormone releasing activity
NL8200523A (nl) 1982-02-11 1983-09-01 Univ Leiden Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna.
US5134120A (en) 1984-08-03 1992-07-28 Cornell Research Foundation, Inc. Use of growth hormone to enhance porcine weight gain
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5036045A (en) * 1985-09-12 1991-07-30 The University Of Virginia Alumni Patents Foundation Method for increasing growth hormone secretion
US4833166A (en) * 1987-05-01 1989-05-23 Grosvenor Clark E Growth hormone releasing hormone complementary peptides
US4839344A (en) * 1987-06-12 1989-06-13 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
USRE33699E (en) 1987-07-09 1991-09-24 International Minerals & Chemical Corp. Growth hormone-releasing factor analogs
FR2622455B1 (fr) 1987-11-04 1991-07-12 Agronomique Inst Nat Rech Application du facteur de stimulation de la secretion de l'hormone de croissance humaine, de ses fragments actifs et des analogues correspondants, pour augmenter la production laitiere et le poids des nouveau-nes chez les mammiferes
US4952500A (en) 1988-02-01 1990-08-28 University Of Georgia Research Foundation, Inc. Cloning systems for Rhodococcus and related bacteria
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5023322A (en) * 1988-08-31 1991-06-11 Mta Kutatas-Es Szervezetelemzo Intezete Analogs of growth hormone releasing factor (GRF) and a method for the preparation thereof
US5084442A (en) 1988-09-06 1992-01-28 Hoffmann-La Roche Inc. Cyclic growth hormone releasing factor analogs and method for the manufacture thereof
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5302523A (en) * 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5137872A (en) 1989-09-18 1992-08-11 Pitman-Moore, Inc. Growth hormone-releasing factor analogs
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
NZ238748A (en) 1990-06-29 1993-09-27 Hoffmann La Roche Growth hormone releasing factor (grf) analogues
US5486505A (en) * 1990-07-24 1996-01-23 Polygen Holding Corporation Polypeptide compounds having growth hormone releasing activity
US5384253A (en) * 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
CA2084061A1 (en) 1991-04-09 1992-10-10 Arthur M. Felix Growth hormone releasing factor analogs
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5663146A (en) * 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
US5925564A (en) * 1991-11-06 1999-07-20 Baylor College Of Medicine Expression vector systems and method of use
US5298422A (en) * 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
JP3368603B2 (ja) * 1992-02-28 2003-01-20 オリンパス光学工業株式会社 遺伝子治療用処置具
US6033884A (en) 1992-03-20 2000-03-07 Baylor College Of Medicine Nucleic acid transporter systems and methods of use
EP1236473A3 (en) 1992-04-03 2003-01-15 The Regents Of The University Of California Self-assembling polynucleotide delivery system
AU685054C (en) 1992-05-14 2003-02-27 Baylor College Of Medicine Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
DE69334225D1 (de) * 1992-07-07 2008-07-31 Japan Tobacco Inc Verfahren zur transformation einer monokotyledon pflanze
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
CA2140910C (en) 1992-07-27 1999-03-23 Jeffrey A. Townsend An improved method of agrobacterium-mediated transformation of cultured soybean cells
DE4228457A1 (de) 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
US5439440A (en) * 1993-04-01 1995-08-08 Genetronics, Inc. Electroporation system with voltage control feedback for clinical applications
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5792747A (en) 1995-01-24 1998-08-11 The Administrators Of The Tulane Educational Fund Highly potent agonists of growth hormone releasing hormone
AU5441096A (en) 1995-04-14 1996-10-30 The Administrators Of The Tulane Eductional Fund Analogs of growth hormone-releasing factor
US5780448A (en) * 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5945100A (en) * 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US6251433B1 (en) * 1996-08-13 2001-06-26 Chiron Corporation Polycationic polymers
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
US5704908A (en) * 1996-10-10 1998-01-06 Genetronics, Inc. Electroporation and iontophoresis catheter with porous balloon
JP2001511353A (ja) * 1997-07-24 2001-08-14 バレンティス・インコーポレーテッド Ghrhの発現システムおよび使用法
US5994624A (en) * 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US6194402B1 (en) * 1998-09-02 2001-02-27 Merck & Co., Inc. Enhancement of return to independent living status with a growth hormone secretagogue
CA2303702A1 (en) * 1999-04-12 2000-10-12 Pfizer Products Inc. Growth hormone and growth hormone releasing hormone compositions
PL366132A1 (en) * 1999-07-26 2005-01-24 Baylor College Of Medicine Super-active porcine growth hormone releasing hormone analog
AR037778A1 (es) * 2001-12-11 2004-12-01 Advisys Inc Suplementacion mediada por plasmido para el tratamiento de sujetos cronicamente enfermos
US7964196B2 (en) * 2004-05-25 2011-06-21 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
US9302725B2 (en) 2013-03-14 2016-04-05 Bell Sports, Inc. Locking rack system for bicycles
WO2015178959A1 (en) 2014-05-19 2015-11-26 Felix Sorkin Modified permanent cap

Also Published As

Publication number Publication date
CA2469310A1 (en) 2003-06-19
US7241744B2 (en) 2007-07-10
CN1615151A (zh) 2005-05-11
US8178504B2 (en) 2012-05-15
EP1465654A4 (en) 2007-08-29
MY142457A (en) 2010-11-30
WO2003049700B1 (en) 2003-10-30
WO2003049700A2 (en) 2003-06-19
TW200301778A (en) 2003-07-16
CA2469310C (en) 2013-01-29
AU2002357143B2 (en) 2009-07-30
MXPA04005713A (es) 2005-06-06
US20090170748A1 (en) 2009-07-02
EP1465654B1 (en) 2015-02-25
BR0214869A (pt) 2005-03-08
EP1465654A2 (en) 2004-10-13
WO2003049700A3 (en) 2003-09-18
US20040057941A1 (en) 2004-03-25
AU2002357143A1 (en) 2003-06-23

Similar Documents

Publication Publication Date Title
AR037778A1 (es) Suplementacion mediada por plasmido para el tratamiento de sujetos cronicamente enfermos
DE60327786D1 (de) Kdr-peptide und diese enthaltende impfstoffe
Del Sal et al. cDNA cloning of the neutrophil bactericidal peptide indolicidin
DK1442058T3 (da) Peptider der er effektive til behandling af tumorer og andre tilstande der kræver fjernelse eller destruktion af celler
EA200800368A1 (ru) Гликозилированный il-7, получение и применение
US3948875A (en) Process for the preparation of epidermal growth factor and new derivative using cross-linked polyacrylamide gel at a pH of 1-3
ATE430161T1 (de) Peptid aus hsp70 welches nk zellaktivtät stimuliert und seine verwendung
KR101807593B1 (ko) 흉터 최소화 상처 재생 촉진용 재조합 폴리펩타이드 및 이를 포함하는 생체 접착 소재
Cordingley Trematode eggshells: novel protein biopolymers
AR037038A1 (es) Una composicion y metodo para alterar la masa corporal magra y las propiedades oseas en un sujeto
DK1201137T3 (da) Cystein-/glycinrige peptider
DK1264599T3 (da) TNF-afledte peptider til anvendelse i behandling af ödem
ATE420191T1 (de) Promotoren zur expression im modifizierten vacciniavirus ankara
AR010337A1 (es) Acido nucleico aislado, molecula de acido nucleico, sonda, vector de expresion recombinante, celula, metodo para producir un polipeptido de h.pylori, metodo para detectar la presencia de un acido nucleico helicobacter, polipeptido de h.pylori aislado, proteina de fusion, formulacion para vacuna
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
PE20212072A1 (es) Composiciones utiles en el tratamiento de la enfermedad de krabbe
AR045000A1 (es) Gen y proteina de eimeria , y su uso
FI20050753A0 (fi) Uudet peptidit
ATE325812T1 (de) Menschliches, gebärmutterkrebs-spezifisches suppressorprotein, für das protein kodieres polynukleotid, mit dem polynukleotid transformierte zelle und verfahren zur unterdrückung der proliferation von krebszellen unter verwendung des expressionsvektors
EP0361956A3 (en) Increased expression of small molecular weight recombinant proteins
AR029130A1 (es) Gen enzimatico y sus productos de expresion
ATE423200T1 (de) Neues plexin-polypeptid, dieses codierende dna und verwendung davon
DE50310131D1 (de) Peptide mit hohem cysteingehalt
CY1109617T1 (el) Ενα πεπτιδιο hsp70 που διεγειρει τη δραστηριοτητα φυσικων φονικων κυτταρων (νκ) και χρησεις αυτου

Legal Events

Date Code Title Description
FA Abandonment or withdrawal